Leveraging Medication-Use Evaluations to Optimize Care: Focus on Andexanet alfa

This on demand webinar is not for CE.

Optimizing patient and organizational outcomes is a priority across healthcare. Well-designed medication-use evaluations are an important quality improvement tool. During this activity, participants will engage with clinical pharmacy leaders to apply a recently released ASHP Foundation medication-use evaluation (MUE) resource guide to examine andexanet alfa use in the management of life-threatening bleeding in patients on direct oral factor Xa inhibitors (DOACs). The resource guide serves as one tool to support your efforts to monitor and improve the care of patients. It is not meant to promote or recommend a specific medication or course of treatment. Participants of the activity will learn strategies to apply a quality improvement framework to conduct rigorous MUEs at their organization.

Learning Objectives:
1. Discuss patient and process considerations for the use of andexanet alfa to manage life-threatening bleeding in patients on direct oral factor Xa inhibitors (DOACs).
2. Apply the ASHP Guidelines and FOCUS-PDCA to customize an MUE to the practice setting.
3. Identify relevant process and outcome measures related to the use of andexanet alfa.
4. Describe strategies to consider when conducting a rigorous MUE.

View the ASHP Foundation resoruce guide here. 

Faculty:

John Fanikos, RPh, MBA (Moderator)
Brigham and Women’s Hospital
Boston, MA

Allison Burnett, PharmD
University of New Mexico
Albuquerque, NM

Anne Rose, PharmD
University of Wisconsin
UW Health
Madison, WI

Sarah A. Spinler, PharmD
School of Pharmacy and Pharmaceutical
Sciences, Binghamton University
Binghamton, NY